# Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

> **NCT05731544** · PHASE1,PHASE2 · COMPLETED · sponsor: **Biomea Fusion Inc.** · enrollment: 443 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** BMF-219

## Key facts

- **NCT ID:** NCT05731544
- **Lead sponsor:** Biomea Fusion Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-17
- **Primary completion:** 2024-11-18
- **Final completion:** 2025-07-08
- **Target enrollment:** 443 (ACTUAL)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05731544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05731544, "Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05731544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*